In addition, the GeparSixto (GBG66) study found that the PCR rate in patients with triple-negative breast cancer in the general group (regardless of BRCA1/2 status) was higher in the carboplatin-treated group (RR 1.87; 95% CI 1.17–2.97; p = 0.009): 41.4% (60 of 145) and 56.8% (83 of 146 patients), respectively. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.